Evidence map›Paper›PMID 38148492›Full record

ArticleCancer science2024

Antipodoplanin antibody enhances the antitumor effects of CTLA-4 blockade against malignant mesothelioma by natural killer cells.

Hiroto Yoneda, Atsushi Mitsuhashi, Aito Yoshida, Hirokazu Ogino, Satoshi Itakura, Na Thi Nguyen, Hiroshi Nokihara, Seidai Sato, Tsutomu Shinohara, Masaki Hanibuchi and 4 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer science, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
1.3field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 2 institutions in 1 country.

Hiroto YonedaDepartment of Respiratory Medicine and Rheumatology, Tokushima University, Tokushima, Japan.
Atsushi MitsuhashiDepartment of Respiratory Medicine and Rheumatology, Tokushima University, Tokushima, Japan.
Aito YoshidaDepartment of Clinical Pharmacy Practice Pedagogy, Tokushima University, Tokushima, Japan.
Hirokazu OginoDepartment of Respiratory Medicine and Rheumatology, Tokushima University, Tokushima, Japan.
Satoshi ItakuraDepartment of Clinical Pharmacy Practice Pedagogy, Tokushima University, Tokushima, Japan.
Na Thi NguyenDepartment of Respiratory Medicine and Rheumatology, Tokushima University, Tokushima, Japan.
Hiroshi NokiharaDepartment of Respiratory Medicine and Rheumatology, Tokushima University, Tokushima, Japan.
Seidai SatoDepartment of Respiratory Medicine and Rheumatology, Tokushima University, Tokushima, Japan.
Tsutomu ShinoharaDepartment of Community Medicine for Respirology, Tokushima University, Tokushima, Japan.
Masaki HanibuchiDepartment of Community Medicine for Respirology, Hematology and Metabolism, Graduate School of Biomedical Sciences, Tokushima University, Tokushima, Japan.
Shinji AbeDepartment of Clinical Pharmacy Practice Pedagogy, Tokushima University, Tokushima, Japan.
Mika K KanekoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.
Yukinari KatoDepartment of Antibody Drug Development, Tohoku University Graduate School of Medicine, Sendai, Japan.ORCID https://orcid.org/0000-0001-5385-8201
Yasuhiko NishiokaDepartment of Respiratory Medicine and Rheumatology, Tokushima University, Tokushima, Japan.ORCID https://orcid.org/0000-0001-6311-1654
Tokushima University · JPTohoku University · JP

Funding

Japan Agency for Medical Research and Development JP21am0101078Japan Agency for Medical Research and Development JP22ama121008Japan Society for the Promotion of Science 19H03668Japan Society for the Promotion of Science 20K07197Japan Society for the Promotion of Science 20K17216
6 · The paper itself

Abstract

Combination immunotherapy with multiple immune checkpoint inhibitors (ICIs) has been approved for various types of malignancies, including malignant pleural mesothelioma (MPM). Podoplanin (PDPN), a transmembrane sialomucin-like glycoprotein, has been investigated as a diagnostic marker and therapeutic target for MPM. We previously generated and developed a PDPN-targeting Ab reagent with high Ab-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC). However, the effects of anti-PDPN Abs on various tumor-infiltrating immune cells and their synergistic effects with ICIs have remained unclear. In the present study, we established a novel rat-mouse chimeric anti-mouse PDPN IgG

Indexed as

MesotheliomaMesothelioma, MalignantAnimalsAntibodies, MonoclonalCHO CellsCricetinaeCricetulusCTLA-4 AntigenKiller Cells, NaturalMembrane GlycoproteinsMiceRatsAntibodies, MonoclonalCTLA-4 AntigenMembrane GlycoproteinsCTLA-4immune checkpoint inhibitormalignant pleural mesotheliomaNK cellpodoplanin

Identifiers

PMID38148492
PMCPMC10859607
OpenAlexW4390270603

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.